Recently, Lead Healthcare, an innovative solutions provider with a keen focus on the neural modulation and brain - computer interface industry chain, made the announcement that it has successfully completed a Series B funding round, raising close to RMB 200 million.

This funding round was co - led by Shunxi Fund and E - Town Capital. Other notable participants included Galaxy Innovation Capital, Guangzhou Industrial Investment Capital, and E - Town Investment.

Since its inception in 2017, Lead Healthcare has been deeply engaged in two key technological platforms: wireless energy transmission and in - vivo chips. The company is dedicated to offering innovative treatment solutions for patients suffering from neurological functional disorders.

The capital raised in this Series B funding round will be mainly allocated to three areas. Firstly, it will support the expansion of the company's product lines, enabling it to introduce a wider range of products to the market. Secondly, the funds will be used for capacity upgrades, which will enhance the company's production capabilities and efficiency. Lastly, a significant portion will be invested in talent acquisition and team building, ensuring that Lead Healthcare has a skilled and motivated workforce to drive its future growth.